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Abstract

Impaired cellular tolerance of reactive oxygen species (ROS) has been
suggested as a common mechanistic link associated with aging in both metabolic
syndrome and nephrolithiasis. The mechanistic (mammalian) target of rapamycin
(mTOR) activity is characteristic of metabolic syndrome. When nutrients are abundant,
mTOR is active. Conversely, fasting inhibits mTOR. Metabolic syndrome is correlated
with an increased risk of self-reported or imaging findings of nephrolithiasis. At the
individual level, patients with a higher BMI have an increased prevalence of recurrent
symptomatic nephrolithiasis, 24-hour urinary excretion of oxalate, sodium, uric acid,
calcium, and phosphorous as well as lower pH. Calcium oxalate crystals produce ROS
in renal epithelial cells and upregulate ROS and also mTOR activity. Rapamycin
pharmacologically inhibits mTOR leading to autophagy – a natural defense mechanism
against ROS – and drives sub-cellular recycling machinery to a net catabolic state.
Ideally, inhibiting mTOR limits the duration and degree of damage done by ROS and
subsequent inflammatory process. Additionally, improved clearance of damaged
organelles prevents runaway generation of ROS by mitochondrial dysfunction
associated with calcium oxalate crystal adherence and internalization. Taken together,
this may prevent the progression of calcium oxalate urolithiasis. In this study, we
examined the effect of short-term intermittent rapamycin treatment on the area of
calcium oxalate concretion in the Malpighian tubules of a Drosophila melanogaster fed a
lithogenic diet containing 0.1% sodium oxalate.
Keywords: nephrolithiasis, rapamycin, mTOR, Drosophila melanogaster, calcium
oxalate, sodium oxalate, Malpighian tubule, aging, metabolic syndrome, reactive oxygen
species, autophagy.
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Lay Summary
We do not know why obesity and aging are risk factors for kidney stones. With obesity and aging, there is
opportunity for damage and stress on the body to keep organs like the kidneys from working like they should. As a
result, we think that this may lead to more risk of forming kidney stones. A pathway called the mTOR pathway might
help explain why older and more obese people form more stones compared to younger fit people. Our project found
that using a drug (rapamycin) to slow down this pathway could lower the ability kidney stones to form in a fruit fly animal
model. The fruit flies given this drug tended to live longer in stressful environments compared to equivalent flies that
did not get this drug. This finding suggests we should design more experiments to block this pathway either through
specific diets, exercises, and/or drug treatments that might one day be tried in humans.
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Chapter 1
Aim
Excessive caloric intake and low physical activity have been associated with a wide
variety of age-related diseases associated with reactive oxygen species including
metabolic syndrome and nephrolithiasis.1 Indeed, elevated body mass index (BMI) is an
independent risk factor for recurrent symptomatic kidney stone episodes.3 Previous
studies have correlated higher BMI to abnormal urinary nephrolithiasis parameters and
recurrent symptomatic stone episodes.2 A major regulator of overall growth in relation to
nutrient availability is the mechanistic/mammalian target of rapamycin (mTOR) pathway.3
When active, the mTOR complex coordinates efficiency of cellular processes depending
on nutrient availability, cell stress and growth factors. Essentially, active mTOR is seen
as a nutrient “checkpoint”, indicating to the cells that the net environmental conditions are
favourable to allow for growth and reproduction. Conversely, processes associated with
lower mTOR activity are involved in breaking down macromolecules. Lower mTOR
activity leads to increased cellular senescence, apoptosis and protein/organelle turnover
through increased autophagy. There is mounting evidence that in complex ageassociated diseases like metabolic syndrome, mTOR is overactive.3–8
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Recently in a dietary rodent model fed ad libitum, calcium oxalate crystal formation
was associated with

activation of mTOR activity and promoted stone formation.9

Importantly mTOR activity can be inhibited, either pharmacologically with rapamycin and
via dietary restriction. Damage of upstream and downstream genes in the mTOR pathway
may also modulate mTOR responsivity and act in concert with ROS to age related
conditions like metabolic syndrome and nephrolithiasis. Drosophila melanogaster (DM)
is a convenient model organism for studying nephrolithiasis due to homology between
human nephrons and DM Malpighian tubules. If altering mTOR activity can be shown to
modulate nephrolithiasis, DM is a uniquely positioned model organism to interrogate how
the mTOR pathway may help prevent nephrolithiasis. In the following thesis, we will
determine whether the mTOR inhibitor rapamycin has an effect on calcium oxalate
concretion formation in a dietary model of calcium oxalate nephrolithiasis in DM.
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Introduction
The importance of managing nephrolithiasis
Nephrolithiasis, commonly known as “kidney stone disease”, can be devastating.
In addition to pain, nephrolithiasis can harbour bacteria and cause bacterial sepsis,
particularly if there is blockage of urine flow by the stone. With each episode of stone, the
possibility for acute kidney injury, ureteral stricture, and complications from treatments
can occur. Chronic kidney disease, defined as a 3 month period of glomerular filtration
rate (GFR) less than 60 ml/min/1.73m2, elevated markers of kidney damage10, can occur
from prolonged obstruction by stone, by stricture, or by recurrent kidney infections.
Observational studies suggest patients with a history of kidney stones are at least twice
as likely as other patients to develop chronic kidney disease (CKD).11 Prospective cohort
multivariate analyses have demonstrated that the risk of end-stage renal dysfunction
(ESRD) requiring renal replacement therapies like dialysis are more than twice as likely
in female patients reporting a history of stones (OR 2.37, 95%CI 1.13-4.96).11,12
A significant contributor to the potential morbidity of stone disease it its recurrent
nature; as any patient with a first episode of stone has around a 50% chance of having a
recurrent episode within 5 years.13 The indirect morbidity of nephrolithiasis is difficult to
quantify yet is significant. A vast majority of trials examining quality of life in kidney stone
patients demonstrate lower quality of life (QoL), bodily pain and general health is worse
in kidney stone patients compared to control patients.14 Longitudinal follow up with a
follow up of 18 months, suggests that there is no difference patient reported QoL as time
from the initial renal colic episode increases.15 There is also a further loss of QoL related
3

to repeat procedures as a result of recurrent stone episodes, as well as potentially
unsuccessful procedures, and complications related to both stone disease and prior
surgical intervention. An estimated 2.1 billion dollars are expended annually in the United
States for the direct management of urolithiasis, a figure that has increased 50% since
1994.27 As nephrolithiasis has its peak in 40s-60s, there is certainly a decrease in work
productivity associated with kidney stones.16 For an average episode of renal colic
managed in the outpatient setting, patients may miss anywhere from 5 to 48 hours of
productive working time.17 If the condition of the patient is such to warrant inpatient
management, the average patient will miss 2-5 days of work.17 Altogether, a review of
indirect costs from privately insured billings show that the total indirect cost of stone
disease may be upwards of $775 million US dollars and 3.1 million days off work per
year.18,19
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Epidemiology of nephrolithiasis
Nephrolithiasis is increasing in prevalence (Figure 1.1).20 In North America, the
prevalence of urolithiasis from 2007 to 2010 was estimated to be 8.8% using the Nutrition
Heath Examination Survey (NHANES) data set.21 Previously, male sex and advanced
age were described as risk factors for stones, but from a global perspective there appears
to be an increase in stone prevalence regardless of sex, ethnicity or age.20,22 Kidney
stone prevalence increased by 16% annually between 1997 and 2012, a pace that
surpassed the increase in obesity over the same time period.23 The increase
in stone prevalence can be partially attributable to the increasing use of cross-sectional
and US imaging. Indeed, the Icelandic group led by Edvardsson found an increase in the
incidence of urolithiasis from 108 per 100 000 people in 1985 – 1990 to 138 per 100 000
people despite no increase in symptomatic stone rates.24
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A

B

Figure 1. 1 Prevalence of nephrolithiasis in the United States of America by decade from
three time periods of NHANES data collection.
Percent prevalence of stones in USA has increased in all age groups by decade in both
(A) men and (B) women. The coloured bars indicate different periods of time that
prevalence data was collected. Figure generated on Microsoft Excel v 16.44 using data
from NHANES I, NHANES II, and NHANES III collection periods. NHANES = National
Health and Nutrition Examination Survey.25,26
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Pathophysiology of nephrolithiasis
Interestingly, Maloney et al have suggested that urolithiasis tends to cluster around
regions more so than ethnicity; therefore, metabolic abnormalities and dietary habits may
outweigh the genetics shared by a particular ethnic group.27 It is also well known that
nephrolithiasis is more prevalent in hot, arid, dry climates like mountains, deserts or the
tropics where people are prone to dehydration. The physical chemistry and pathogenesis
of stones are not fully understood; however, reduced fluid intake is inarguably an
important mediator of stone formation. At a minimum the supersaturation and nucleation
of solutes in urine is required.28 Nephrolithiasis formation begins at the level of the
nephron with the filtration of blood and supersaturation of stone-forming ions in urine.
Supersaturation occurs when the concentration product exceeds the solubility product of
solutes in urine. Importantly, stone inhibitors in urine greatly increase the solubility product
of solutes in urine compared to aqueous solutions lacking these inhibitors. When the
concentration product exceeds the metastable range of urine with stone inhibitors in
solution, crystal precipitation may occur. This is known as the formation product. In other
words, below the solubility product stone crystal formation will not occur, and
concentrations of solute above the formation product will lead to stones. Increasing the
range of the metastable zone is therefore the focus of prevention of kidney stones.29
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Once the formation product level of salt-forming substances is reached, crystals
require an anchoring site to provide time for crystal growth in order for crystals to reach a
clinically relevant size. Under normal conditions, the time required for filtered blood to
become urine and pass though the renal collecting system into the bladder via the ureter
does not provide sufficient time to allow for significant crystal growth.30 However,
blockage or “plugging” the collecting ducts of the nephron, local areas of urinary stasis,
established stone/crystals, damaged cells or even foreign/native materials not normally
in the urine can contribute to nidus for stone growth by providing an anchoring site.28,30

Non-calcium nephrolithiasis
Stones are classified according to their composition, and are broadly divided into
calcium containing stones (oxalate, hydroxyapatite, brushite) and non-calcium containing
stones (uric acid, struvite, cystine, triamterene, ammonia, silica, drug and matrix stones).
31

For each of these types of stones, the chemistry of stone formation varies greatly and

inhibitors for one type may not impact others. Although the metabolic syndrome may be
associated with both uric acid and calcium oxalate stones, for the purpose of this thesis
only calcium-based stones will be considered.
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Calcium based nephrolithiasis
Calcium based stones are responsible for approximately 80% of urolithiasis cases
in the industrial world.32 Calcium oxalate stones may be either monohydrate or dihydrate
and may have a minor or major component of phosphate. Primary calcium phosphate
monohydrate (brushite) stones are more rare than calcium oxalate stones but make up
approximately 15% of patients with nephrolithiasis.33 Calcium homeostasis is a complex
process involving the parathyroid glands, kidneys, small intestine, and bone.

34

Calcium

is absorbed in its ionic state; therefore, impaired calcium absorption can occur when
complexed with phosphate, citrate, oxalate, sulfate and fatty acids from diet. As a result,
about 600 – 1200mg of calcium intake will lead to about 100 – 300 mg of absorption,
primarily by the small bowel. When calcium is low, parathyroid hormone (PTH) through a
vitamin D-dependent pathway is required to enhance the transcellular absorption of
calcium at the brush border of intestinal epithelia and maximize calcium resorption from
kidney. Only about 1-3% of filtered calcium is excreted in the urine due to calcium
resorption by the kidney; and areas of the kidney most active in calcium homeostasis
include the proximal tubule (60-65%) and thick ascending limb of loop of Henle (25-30%)
with the rest being reabsorbed transcellularly in the distal convoluted tubule.
Hypercalciuria, or elevated calcium in the urine, is the most common metabolic
abnormality associated with calcium-based stones and may result from any abnormality
of the usual calcium homeostasis mechanism.35
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Randall’s plaques and progression of nephrolithiasis
There are two main theories regarding the growth of kidney stone crystals. Free
particle stone theory requires the crystallization to occur within the nephron. The former
theory is supported by the observation that nephron dimensions and physiologic
parameters of crystal growth are biologically possible.30 Furthermore, there is evidence
of intermedullary collecting duct “plugs” in certain stone-formers.36–38

Fixed particle

growth theory assumes that crystal adherence occurs around a stationary “anchor site”,
providing a favorable environment for growth.39 The stationary site may be exogenous
(foreign body) or endogenous in the form of different types of crystals (calcium oxalate
stone developing on a calcium phosphate or matrix nucleus), a previous collecting duct
“plug”, or on a Randall’s plaque. Randall’s plaques are thought to provide a potential nidus
for stone formation. Important work by Evans et al. on renal papillae specimens following
percutaneous surgery to treat idiopathic calcium oxalate stones revealed that a Randall’s
plaque may be sub-epithelial and localized to the thin ascending loop of Henle at the level
of the renal papilla.36 They are composed of matrix and calcium apatite material which
erode through the urothelium of the renal papilla in order to contact urine and produce
stones. Indeed, of 5000 calcium oxalate stones analyzed, calcium apatite stone nidus
was present almost universally in calcium oxalate stone formers.40
Randall’s plaques are thought to be vascular in origin and vascular injury and
subsequent repair to the vasa recta or conversion of smooth muscle in nearby blood
vessels from a contractile to a secretory phenotype may contribute to the process of
erosion through the urothelium.41,42
10

Khan et al. provided a unified theory combining both elements of free and fixed crystal
theory.42 In this unified theory, an excess of stone forming substrate, or a lack of stone
inhibitors may lead to free crystals. Upon contact with these free crystals, renal epithelial
cells may become overwhelmed with maintaining homeostasis causing an increase in
oxidative stress which subsequently results in paracrine signalling, inflammation and dedifferentiation of nearby cells. Some cells may then acquire a secretory phenotype and
deposit calcium phosphate crystals, and this combined with increased sub-epithelial
metabolism of connective tissue may promote the growth of a plaque. With time and
further metabolism, the plaque erodes through the epithelium where it can be exposed to
urine and stone may form.42

Reactive oxygen species, and nephrolithiasis
Reactive oxygen species (ROS) are unstable oxygen containing molecules
that easily react with other macromolecules.43 At high levels, they damage organelles and
lead to mitochondrial dysfunction contributing significantly to inflammation and cell
death.44 Autophagy – the process a cell uses to break down its own macromolecule
polymers – is a mechanism for resistance to cellular stress created by ROS.44 Adhesion
and internalization of calcium oxalate crystals in the renal tubular epithelium results in
upregulation of several genes involved in energy metabolism including a major source of
ROS, NADPH oxidase, at the level of the mitochondria.45 Excessive apoptosis, inefficient
autophagy

and

locoregional

inflammatory

nephrolithiasis.46
11

signalling

exacerbates

calcium

Inflammation may trigger mineralization of renal interstitial collagen, assisting the growth
of Randall’s plaques and eventual renal epithelial sloughing.47 Previous authors have
shown that treatment strategies directed at reducing generation of ROS like
administration of antioxidant N-acetylcysteine or NADPH oxidase inhibitor apocynin can
reduce ROS, prevent mitochondrial dysfunction and subsequently reduce nephrolithiasis
progression in a lab model.48
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Inhibitors of nephrolithiasis
The presence of naturally occurring stone inhibitors in solution explains why
supersaturated urine does not necessarily lead to crystal nucleation, growth, aggregation
and adherence to renal epithelium.28 Indeed non-stone formers appear to have more
stone inhibitors in their urine compared to those who form stones.49,50 These inhibitors
range from ions to large multi-residue amino acids produced at the level of the nephron.
Small molecules that have shown the ability to raise the solubility of calcium-based stones
include inorganic citrate, pyrophosphate, and, magnesium.51 In an ex-vivo model of
supersaturated calcium phosphate solution, the combination of inorganic pyrophosphate,
citrate and magnesium contributed to approximately 20% of the inhibitory effect of whole
urine on calcium phosphate crystal formation. The role of citrate in stone prevention relies
on its presence in urine as a complex with calcium, thereby preventing association of
calcium with oxalate or phosphate. Citrate also leads to alkalinization of urine and
exacerbate calcium phosphate stones if urine pH is too alkaline.35 Magnesium may
chelate with oxalate with a much higher affinity than calcium, reducing the opportunity for
calcium and oxalate molecules to complex.52
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Macromolecules involved in stone inhibition include glycosaminoglycans, acid
mucopolysaccharide, RNA, and glycoproteins.28,53 In this class of inhibitors, extensive
intracellular processing in the rough endoplasmic reticulum and post-translational
modifications prior to secretion are required for proper physiologic function. Heparin
sulfate is the most commonly referenced stone-inhibiting glycosaminoglycan, and is
consistently found in lower concentrations in recurrent calcium oxalate monohydrate
stone formers compared to non-stone formers.54,5549,50 Conversely, glycosaminoglycans
appear to be a significant component of apatite matrix in plaques found in Randall’s
plaques.56 Others have suggested that this observation may be simply non-selective
presence in matrix due to their relative abundance in urine as albumin and uromodulin
are also present in high amounts.49 Rather, highly anionic proteins and cationic proteins
normally found in the intracellular or nuclear compartments represent a disproportionate
percentage of stone matrix compared to their abundance in urine.49
There are also several glycoproteins that may act as stone inhibitors; however, the
two most important are nephrocalcin and Tamm Horsfall protein (THP) or uromodulin.57
Nephrocalcin is a highly acidic protein with four isoforms produced by renal epithelial cells
in the proximal tubule and thick ascending loop of Henle.28 Different isoforms of
nephrocalcin have been shown to have different gamma-carboxygltamic acid residues
and thus varying affinities for calcium. This may be clinically relevant as human stone
formers have been shown to fewer of the strong-inhibitor isoforms and instead produce
more weak-inhibitor isoforms.58,59 In addition, all isoforms sampled from stone-formers
had fewer gamma-carboxyglutamic acid residues compared to equivalent isoforms from
non-stone formers.58,60
14

THP is the most common protein found in human urine and is produced by the
renal epithelia of the thick ascending loop of Henle and distal convoluted tubule. It is a
membrane-anchored protein that requires cleavage by phospholipase or protease for
release into urine where it likely has multiple roles including prevention of urinary tract
infections (UTIs), inhibition of calcium oxalate monohydrate crystal aggregation in alkaline
urine, and as a regulator of endocytosis of TRPV5 and TRPV6 channels required for
transcellular Ca2+ resorption in the kidney.28,59,61 Indeed genome-wide association studies
as well as animal knockout models suggest that THP is a significant inhibitor of calcium
oxalate nephrolithiasis.41,62,63However, in acidic urine, THP has the potential to change
conformation and polymerize such that it encourages crystal aggregation, facilitating
potential nidus for stone.53
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General prevention of nephrolithiasis
Preventative strategies have in the past focused on addressing dietary ,
anatomical and metabolic risk factors; however, the complete pathophysiology underlying
these recommendations is not known.28,64 General advice includes increased fluid intake
to produce >2L urine per day after first stone episode, avoiding dehydration (occupational
or adverse arid climate exposure), reducing dietary sodium/animal products, and
identifying underlying medical or anatomic reason for stone formation.35 Unfortunately,
there is currently no evidence in favor of the primary prevention of nephrolithiasis.65
Secondary prevention can be achieved through the targeting of identifiable metabolic
stone parameters, for example increasing citrate intake, moderating oxalate intake, and
ensuring adequate calcium intake.35 Much of the difficulty in providing new effective
recommendations, particularly when there is no identifiable risk factor, relates to the
relative lack of animal models of nephrolithiasis in the context of reactive oxygen species
generated by metabolic syndrome.64
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mTOR and nephrolithiasis
The association of metabolic syndrome with calcium oxalate urolithiasis is an
active area of current research.64 In particular, ROS associated with metabolic syndrome
may increase biomineralization on Randall’s plaques and exacerbate oxidative damage
from hyperoxaluria.41,66 Calcium oxalate crystal adherence to renal urothelium triggers
an inflammatory cascade and has been shown to exacerbates stone formation in both in
vivo and in vitro models.9,67 Furthermore, ROS may upregulate epithelial to mesenchymal
transition (EMT) of renal epithelial cells to osteoblast-like cells and the ensuing formation
of Randall’s plaques.47 In addition, further mesenchymal activity results in the excessive
production of matrix degrading proteins and enzymes thereby allowing the plaques to
erode through the urothelium and produce a nidus for stone formation.
Interestingly, mTOR has been described to affect both EMT as well as
inflammatory responses in various other tissues including cervical68, pulmonary69 and
renal tissues affected by diabetic nephropathy70. Although there is a paucity of data in the
literature, there have been suggestions that mTOR is implicated in the pathogenesis of
obesity-associated renal tubulointerstitial inflammation and urolithiasis.41,71 In one study
comparing 27 non-obese to 35 obese patients, urinary markers of tubulointerstitial
inflammation including monocyte chemoattractant protein 1 (MCP-1) and neutrophil
gelatinase associated lipocalin (NGAL) were elevated in the obese cohort.41 Furthermore,
examination of kidneys from a high-fat diet rat model of obesity showed evidence of
increased inflammation that was reversed by rapamycin treatment.71
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Metabolic syndrome, aging, and, nephrolithiasis
Interestingly, stone disease is increasing in parallel with the increasing prevalence
of metabolic syndrome, which affects 1 in 4 Americans and is rising in pediatric
populations.

1,72

Metabolic syndrome has multiple definitions. However, it is universally

defined by the presence of insulin resistance, obesity, hypertension, and dyslipidemia
and leads to an increased risk of cardiovascular disease and accelerated
atherosclerosis.1,72,73 A meta-analysis of large retrospective datasets suggests that
metabolic syndrome is correlated with increased risk of self-reported or imaging findings
of urinary stone disease.73 At the individual level, patients with a higher BMI have
increased prevalence of recurrent symptomatic urolithiasis, 24-hour urinary excretion of
oxalate, sodium, uric acid, calcium, and phosphorous as well as lower urine pH.74,75
Hyperinsulinemia, an eventual end result of the metabolic syndrome, has been
associated with hypercalciuria in obese patients who form stones.76,77 The risk of calcium
and uric acid based stones is higher for obese individuals.2,78 Furthermore, even with
accounting for confounding risk factors, nephrolithiasis has been associated with the
complications of metabolic syndrome, specifically myocardial infarction and accelerated
atherosclerosis.
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There exists differences in the rates of urinary stone disease amongst different
racial groups. Despite all ethnicities suffering the burden of urolithiasis, the highest
prevalence of nephrolithiasis is in Caucasians and is positively correlated with income
and a sedentary lifestyle.25

For example, Soucie et al has shown that the highest

prevalence of stone disease in Caucasians followed by Hispanic, Asian, and, African
Americans.79 Examination of emergency department demonstrate differences in the
gender predominance of stone disease in different ethnicities. For example, Dall’era et al
showed a male to female ratio of 2.05 for Caucasians compared to 1.17 for Hispanics.
Furthermore, Sarmina et al in 1987 described an incidence in symptomatic nephrolithiasis
with a male: female ratio of 2.03 in Caucasians vs a 0.63 ratio in African Americans.80
This finding of increased male predominance appears to hold true today, however the
authors of a study in South Carolina in 2019 have suggested that the greatest increase
in stone disease were observed in adolescents, females and African American patients.23
Strikingly, the prevalence of stone disease doubled in children and there was a 45%
increase in lifetime risk in women over the course of this study period.23
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Age has an interesting relationship with both nephrolithiasis and metabolic
syndrome. According to Stats Canada, the percentage of adults who are obese increases
with increasing age.81 Between the ages of 40 and 60, over 70% of men and 60% of
women are obese or overweight in Canada.81 In contrast, 8.5% of children aged 5 to 9
years old are obese; however the prevalence appears to be rising.82 Historically, the
incidence of nephrolithiasis peaks beginning at age 40 and is more common until age 60;
however, in parallel to the increasing rates of obesity, it is becoming more common for
kidney stones to affect people under the age of 20.28.83,84 Interrogation into a national
pediatric database including all admissions, emergency and outpatient visits from 1999 –
2008 related to nephrolithiasis revealed an increase in paediatric patients treated for
stones from 18.4 per 100 000 in 1999 to 57 per 100 000 in 2008.85 Although consistent
evidence exists for a trend in the annual increase in pediatric nephrolithiasis, the
pathophysiology behind this observation has been elusive. Ultimately, obesity and
metabolic syndrome have been suggested as comorbid conditions that may have a role
in promoting nephrolithiasis, or share common risk factors, with nephrolithiasis
formation.2,23
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mTOR pathway and metabolic syndrome
Recently, the mTOR pathway has been suggested as a key pathway at the
crossroads of urolithiasis and metabolic syndrome. mTOR is a highly conserved
serine/threonine protein kinase recognized as a central coordinator of growth and
metabolism which is found from yeasts to higher order organisms including insects and
mammals (Figure 1.2).86
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Figure 1. 2 An overview of the mTOR pathway as a mediator of the correlation between
metabolic syndrome and nephrolithiasis.
The positive influence of various pro-growth signals including growth factors, abundant
micronutrients and environmental stimuli lead to an increase in mTOR activity. The
aggregate effects of mTOR activity are pro-anabolic at the cellular level. In general, tissue
growth leads to the metabolic syndrome phenotype. In parallel, the effects of mTOR
specifically at the local level of the kidney or gastrointestinal (GI) tract may promote
nephrolithiasis by several mechanisms correlated with increased mTOR activity. For
example, an increase in protein synthesis and post-translational processing may lead to
an increase in defects in the processing of macromolecules.Defective macromolecules
may still function reasonably well in most cases, but stone inhibitor proteins that are
associated with nephrolithiasis might not provide the same protection against kidney
stones. The impact of reduced mTOR activity on tissue repair and turnover may
accelerate the erosion of Randall’s plaques. Altered reactive oxygen species and
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epithelial barrier function of GI tract and kidney urothelium may also be affected by mTOR
inhibition or rapamycin directly.
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When mTOR is activated, its core protein (Figure 1.3A) joins other proteins to form
one of two complexes: mTORC1 or mTORC2 (Figure 1.3B and 1.3C). The appropriate
subcellular location and specification of mTORC1 is defined by the binding of mTOR to
the regulatory protein associated with mTOR (Raptor).3 Raptor is a scaffolding protein
that facilitates and stabilizes protein-protein interactions for mTOR substrate proteins to
the TOR signaling motif (TOS). In addition, mTOR associated protein, LST8 homolog
(mLST8) and Deptor proteins are also required for mTORC1 activity, as it helps stabilize
the active catalytic site of mTOR protein kinase domain (Figure 1.3B).3,87,88
Tuberous sclerosis complex (TSC) protein is an upstream regulator of mTORC1
(Figure 1.4A).

3

When TSC is active, it inhibits mTORC1. Canonical signaling cascades

impacting mTORC1 activity include IGF-1/AKT/PTEN, MAPK-Erk, Wnt and TNF-alpha
pathways.87 In particular, ATP deprivation during starvation activates AMPK. The active
AMPK protein then inhibits mTORC1 via Raptor phosphorylation. Ultimately, ATP
deprivation leads to activation of TSC2 through the signalling cascade above.88,89
CASTOR is another component of mTORC1 that allows for detection of lysosomal
amino acid concentrations.90 When amino acids are present in adequate amounts,
RagGTPases bind to CASTOR. When CASTOR is bound by RagGTPase, there is a
conformational change that occurs increases Raptor’s affinity its mTOR binding site,
stabilizing the mTORC1 complex. Therefore, effective mTORC1 signaling is only possible
with appropriate growth signals and nutrient availability.86
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mTORC1 activity couples growth signals with nutrients available in the
extracellular milleu in order to promote anabolic cellular activities (Figure 1.4B). S6 Kinase
(S6K) is downstream of mTORC1 activity and is the protein responsible for the initiation
of mRNA translation/processing.61 Transcription factors required for de novo lipid
synthesis are regulated by mTORC1 through the sterol responsive element binding
protein (SREBP), which is activated through the activation of S6K and the inhibition of
Lipin 1.86 In addition, de novo purine and pyrimidine synthesis is upregulated through
mTORC1 activity.3,4 Finally, through hypoxia inducing factor alpha (HIF1a) and c-Myc
mTORC1 activity leads to increased glycolysis. Through this process, NADPH and other
intermediates of the citric acid cycle are produced which use abundant environmental
energy and macromolecules and promote organism growth.91
Importantly, mTORC1 activity is associated with reduced autophagy. When
nutrients are abundant, mTORC1 acts via AMPK to phosphorylate and inhibit ULK1,
which subsequently serves to inhibit autophagy. In addition to impairment of apoptosis
under inappropriate conditions, lysosomal biogenesis and creation of proteins required
for autophagy machinery is inhibited by mTOR through protein TFEB. Therefore, active
mTORC1 appropriately limits macromolecule recycling through autophagy in settings
where building blocks for such macromolecules are available in the environment (Figure
1.5A).
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In contrast, mTORC2 is responsible for cellular proliferation, cell-cell interactions
and cytoskeletal rearrangement (Figure 1.4B and 1.5B). mTORC2 is defined by mTOR
binding to rapamycin insensitive companion of mTOR (RIctor) in addition to mLST8. The
rapamycin-FKBP12 complex does not bind to mTOR when it is bound to Rictor as
mTORC2, however chronic use of rapamycin may limit the number of mTOR molecules
and lead to insulin resistance as it can inhibit the downstream AKT/PKB pathway.92
Downstream actions of mTORC2 includes cytoskeletal remodeling and insulin signalling.
In addition, mTORC2 is also involved in cell survival, endocytosis/exocytosis, and ion
transportation through the regulation of serine/theonine-protein kinase-1 (SGK1) (Figure
1.5B).3
In summary, the physiologic role of mTOR is conserved in a wide range of species.
These are accomplished through two protein complexes: mTORC1 and mTORC2 that
have different downstream pathways. Common intracellular processes involving mTOR
include glucose homeostasis, adipogenesis, lean mass homeostasis, immune function,
autophagy associated with aging and cellular proliferation.3,86 Since the mTOR pathway
controls the cell recognizing cues to grow in its environment, manipulation of this pathway
may influence the development of metabolic syndrome and likely other physiologic
processes dependent on the trafficking of solutes such as nephrolithiasis (Figure 1.2).
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Figure 1. 3 (A) The core mTOR protein has several domains required for proper function
and regulation.
The mTOR core protein executes its function via its kinase domain near the c-terminus
of the protein. HEAT = Huntingtin, Elongation Factor 3, Protein Phosphatase 2A, mTOR
(acronym of four proteins in which this repeat structure is found), FAT = Focal Adhesion
kinase Targeting, FRB = FKBP12-Rapamycin Binding, FATC= Focal Adhesion kinase
Targeting C-terminal. (B) The mTORC1 complex is defined by the interaction of the
mTOR core protein with a scaffold protein called Raptor. Rapamycin inhibits mTORC1
complex activity by complexing with FKBP12 and binding the mTOR core protein FRB
domain. The regulation of mTORC1 is complex and can occur through interactions at
other domains. For example, the PRAS40 protein inhibits Raptor’s ability to complex with
the mTOR core protein. Other proteins known to inhibit mTORC1 complex activity
independent of Rapamycin-FKBP12 include Deptor and mLST8. Raptor = Regulatory
associated protein of mTOR. PRAS40 = proline rich Akt (acutely transforming retrovirus
AKT8 in rodent T cell lymphoma) substrate of 40 kDa. FKBP12 = FK506/Tacrolimus
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Binding Protein 12. (C) The mTORC2 complex is defined by interactions with the Rictor
protein.
In order for Rictor to complex with the mTOR core protein, Protor1/2 and mSin1 must be
present. Note: Rapamycin-FKBP12 does not directly inhibit mTORC2. Other proteins
known to inhibit both the mTORC1 and mTORC2 complexes, independent of RapamycinFKBP12. These include Deptor and mLST8. Raptor = Regulatory associated protein of
mTOR.

Rictor = Rapamycin insensitive companion of mTOR, Protor1/2 = Protein

observed with Rictor 1 and 2, mSin1 = mammalian stress-activated protein kinase
interacting protein 1, Deptor = DEP (Dishevelled, Egl-10, Plekstrin) domain containing
mTOR-interacting protein. mLST8 = mammalian Lethal with SEC13 protein 8.3

A
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Figure 1. 4 Negative regulators of mTORC1 and mTORC2.
In the absence of amino acids and growth factor activity, mTORC1 is sequestered by
CASTOR1 protein in the cytoplasm of the cell. Furthermore, scaffold protein Rictor is not
activated by Rheb and lysosomal scaffold composed of Rag proteins are not assembled.
Inactivity of mTORC2 is maintained by conversion of PIP3 to PIP2 by PTEN and Ras
sequestering by NF1. (B) Major positive regulators of mTORC1 and mTORC2. Amino
acids, particularly arginine and leucine are necessary but not sufficient for mTOR activity
by preventing CASTOR protein sequestering of mTORC1. Insulin, FGF and EGF are key
growth factors that promote mTOR activity via their G-coupled protein receptors and
downstream intracellular signalling pathways involving phosphoinositol metabolism and
Ras cascade. The active mTORC2 affects Akt and vice versa, potentiating the
downstream effects of both insulin-response and mTORC2 signalling pathways. Finally,
the insulin and fibroblast/epidermal growth factor pathways, as well as the products of
inflammatory signalling via NF-κB, lead to inhibition of the TSC1/2 complex and permit
mTORC1 localization at level of the lysosome whereby it is required to function. CASTOR
= Cytosolic arginine sensor for mechanistic target of rapamycin complex 1, Rag =
Recombination activating gene, Ragulator = Regulator of Rag, v-ATPase = v-Type
adenosinetriphosphatase, SLC38A9 = Solute carrier family 38 member 9, Rheb = Ras
homolog enriched in brain, IRS = insulin response substrate, PI3K = Phosphoinositol-3kinase, PIP = Phosphatidylinositol, PIP-2 = Phosphatidylinositol 4,5-bisphosphate, PIP-3
= Phosphatidylinositol 2,4,5-trisphosphate, AKT = Ak strain transforming, PKD1 =
Polycistin 1, Ras = Rat sarcoma protein, Raf = Rapidly accelerated fibrosarcoma protein,
MEK = Mitogen-activated protein kinase/extracellular signal-regulated kinase, ERK =
Extracellular regulated kinase, TSC1/2 = Tuberous sclerosis complex 1 and 2, TNF-α =
Tumour necrosis alpha, IKK α = IκB kinase alpha, GSK3B = Glycogen synthase kinase
3B, LKB1 = Liver kinase B1, AMPK = AMP-activated protein kinase, PTEN =
Phosphatase and tensin homolog protein, NF-1 = Neurofibromatosis type 1 protein.3
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Figure 1. 5 The downstream effects of mTORC1 and mTORC2 signalling normally
complement one another.
(A) The mTORC1 complex is responsible for the increase in basic anabolic properties of
mTOR activity like increased glucose utilization, mRNA translation, positive net protein
balance and cellular supply of nucleotides, sterols. S6K = Serine-6-Kinase Protein, 4EBP
= 4E-Binding Protein, ATF1 = Activating Transcription Factor 1, TFEB = Transcription
factor EB, SREBP = Sterol Regulatory Element Binding Proteins/, HIF1α = Hypoxia
Inducible Factor 1-alpha, PGC1 α = Peroxisome proliferator activated receptor Gamma
Coactivator 1-alpha, ATF4= Activating Transcription Factor 4. (B) The mTORC2 complex
is chiefly involved in survival processes of the cell undergoing stress including cell motility
and ion/fluid regulation. SGK = Serine/Threonine-protein Kinase, Foxo1/3a = forkhead
box class-O protein 1 and 3a, PKC = Protein Kinase C, AKT = Ak strain Transforming
protein.3
Autophagy and mTOR
Autophagy is a catabolic process that lies at the interface of reactive oxygen
species and cell stress response.93 The goal of autophagy is to degrade damaged
organelles or proteins in order to release stored energy or re-purpose nutrients that the
cell requires.94 The first step in autophagy involves ROS or reactive nitrogen species
(RNS) triggering signalling cascades.95 Subsequently, rearrangement of cytoplasm
compartmentalizes the substance of interest to be degraded into autophagosomes.94
Autophagosomes then fuse with lysosomes where hydrolase enzymes catalyze
degradation.96
mTOR dependent phosphorylation of ATG13 suppresses ULK1 and prevents
activation by AMPK a key activator of autophagy.94,95 mTOR regulates lysosomal function
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and biogenesis through phosphorylation of TFEB that keeps it in a cytosolic location when
active.90
Autophagy can also be regulated by ROS and other pathways in a non-mTOR dependent
manners, adding to the complexity of this process.97 Age-related diseases like metabolic
syndrome and cardiovascular disease exhibit reduced efficiency of autophagy.98
Inefficient autophagy results in impaired tolerance of ROS and subsequent cell death or
further damage99

Rapamycin and inhibition of mTOR
Rapamycin is a molecule isolated from Streptomyces hygroscopius found in the
soil of Easter Island (Rapa Nui).100 Rapamycin requires a protein called FKBP12 in order
to inhibit mTOR.101 The rapamycin-FKBP complex is an allosteric partial inhibitor of
mTORC1 kinase and binds directly to mTOR at its FRB domain3. Therefore, when mTOR
is inhibited by rapamycin, catabolic processes such as autophagy are upregulated and
drive sub-cellular recycling machinery. In addition, PI3 kinase signaling required for
insulin signaling is inhibited by rapamycin.102,103 The benefits of mTORC1 inhibition may
be limited to acute dosing of rapamycin; however, as chronic exposure to rapamycin may
exacerbate diabetogenic phenotypes.104 With less mTOR protein available to form
mTORC2, cells cannot orchestrate subsequent processes required for appropriate
glucose homeostasis.105
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Clinical Uses of Rapamycin and Side-Effects
Rapamycin is indicated in the treatment of lymphangioleiomyomatosis,106 as part
of immunosuppression regime for renal transplant107 and a component of drug eluting
stents for percutaneous coronary artery revascularization after myocardial infarction.108
Rapamycin has also been used off-label to treat autosomal dominant polycystic kidney
disease (ADPKD),109 renal angiomyolipomas,110 and other solid-organ transplants (heart,
lung, and liver).111 Renal transplant immunosuppression regimes may include rapamycin
mycophenolate mofetil but usually include prednisone induction, a calcineurin inhibitor
(cyclosporin or tacrolimus) or mycophenolate mofetil.112 To our knowledge, rapamycin (or
immunosuppression in general) has never been suggested as part of a preventative
strategy for nephrolithiasis.
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Importantly, rapamycin has well described serious complications from chronic use:
type 2 diabetes mellitus, hypertriglyceridemia, bone marrow toxicity (anemia 12-76%,
leukopenia 11%, thrombocytopenia 30%), gastrointestinal irritation (15-20%), oral ulcers
(10-19%),

thromboembolic

diseases

(17%),

interstitial

lung

disease

(4-17%),

angioedema/lymphedema (2.2-15%), proteinuria (10%), glomerulonephritis (2%).111 The
therapeutic range of rapamycin to avoid toxicity while preventing renal transplant rejection
is between 4-20 µg/L.113 Oral bioavailability of sirolimus is approximately 15% with a large
volume of distribution in humans including in red blood cells and fatty tissues (5.6-16.7
L/kg).114 The half-life of rapamycin is dependent on metabolism by cytochrome P-450 3A4
(CYP3A4).114 Rapamycin is rapidly absorbed, metabolized with time to peak dose of 1
hour, and has a half-life between 39.3 – 86.5 hours.115 CYP3A4 has many substrates
including estradiol and may explain some of the variation in drug clearance between men
and women.114,115
Specifically, rapamycin has been associated with obesity and metabolic syndrome
in the kidney transplant population.116 Several studies have shown an increased risk of
developing new-onset type 2 diabetes mellitus (NOTDM) after conversion from a
calcineurin inhibitor to rapamycin (sirolimus) as part of immunosuppression rejection
prophylaxis.117–119 Additionally, NOTDM has been associated with an increased
cardiovascular mortality and hypertriglyceridemia after kidney transplant.120 Despite a
high prevalence of obesity and metabolic syndrome in the kidney transplant population,
the incidence of kidney stones is reported between 1-1.7% it is generally a rare
complication and some argue lower than in the general population.121,122
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Clinical correlate of overactive mTOR: Autosomal dominant polycystic kidney
disease and risk of nephrolithiasis
Autosomal dominant polycystic kidney disease (ADPKD) is the most common
hereditary kidney disease with a prevalence of 1 in 1000 to 1 in 2500 individuals.123 It is
characterized by multiple cysts affecting both kidneys. Individuals with ADPKD typically
develop urolithiasis earlier than the general population, at a median age of 37.83,123 The
formation of urolithiasis in ADPKD patients has been associated with higher rates of
hyperoxaluria and decreased ammonia excretion.85 Mao and colleagues have shown that
the formation of urolithiasis in ADPKD patients is associated with higher rates of
hypocitraturia, hypomagnesuria, low urine pH, impaired uric acid metabolism, and
hypophosphatemia compared to stone formers without ADPKD.124 Additionally, ADPKD
patients have been shown to have an increased incidence of post-transplant diabetes
mellitus, lipid abnormalities and cardiovascular disease risk compared to all renal
transplant recipients.124
A multitude of genes are associated with this condition, however the most classical
genes are PKD1 and PKD2 and are typically inherited in an autosomal dominant
manner.125 However, ADPKD has also been described to occur without a positive family
history; implying a possible de-novo mutation, germline/somatic mosaicism or epigenetic
changes to PKD1/PKD2 gene products.126
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Loss of these proteins lead to reduced intracellular calcium and reduced PDE1
activity, resulting in excessive cAMP production and cystogenesis through activation of
proliferation and secretion pathways.127 In the absence of PKD1, there is aberrantly active
mTOR, and in fact high levels of mTOR activity have been observed in models of
ADPKD.88This may result through the interactions of PC1 and TSC2 which typically inhibit
mTORC1 formation and is known to be inactivated in certain models of ADPKD.88
Historically, the development of nephrolithiasis in ADPKD has been thought to be
related to CKD and mechanical obstruction from the size of cysts.128 Recommendations
for these individuals includes maintaining a healthy lifestyle and diet, avoiding smoking
and

non-steroidal anti-inflammatory medications (NSAIDs).129 Vasopressin receptor

inhibition, either through drinking water or tolvaptan, leads to decreased cAMP and may
prevent downstream activation of mTOR and other pro-growth pathways; thereby
decreasing cystogenesis.129 Initial murine models investigating mTOR inhibition were
promising in preventing the progression of PCKD; however, phase 3 clinical trials
assessing everolimus and rapamycin failed to demonstrate decreased disease
progression indicated by total kidney volume.109,128
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Calcium oxalate crystals activate mTOR and exacerbate nephrolithiasis
Unno et al recently suggested that autophagy is crucial in ensuring an appropriate
homeostatic response to calcium oxalate monohydrate exposure and that this can be
perturbed by an abundance of calcium oxalate monohydrate in the environment. In
addition, less calcium oxalate monohydrate was required in the presence of an autophagy
inhibitor 3-methyladenine. Finally, a more select mTORC1 inhibitor called Torin1 was
shown to increase autophagy and may protect cells from the effect of downregulated
autophagy caused by calcium oxalate monohydrate exposure. With more efficient
autophagy, less inflammation and crystal aggregation was observed.
Importantly, when mice were treated with rapamycin after 4 days of oxalate
administration, they had less calcium oxalate crystal deposition in their kidneys. The
authors concluded that increased mTOR activity is a major cause of compromised
autophagy by oxalate administration and that this can be remedied by mTOR inhibition in
vivo. 9 The presence of phosphorylated SQSTM1, which serves as a marker of impaired
autophagy, has been shown to be present in the renal mucosa of stone-forming kidney
specimens, and conversely lacking in non-stone forming samples.9
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Drosophila melanogaster as a model of nephrolithiasis
DM has been used as a model organism to study the effects of rapamycin and
mTOR as well as obesity, heart disease, insulin signaling and ROS generation in
metabolic syndrome-like states.130–132 When DM is subjected to excess exogenous fat,
cardiac cells and liver cells accumulate fat in addition to elevated hemolymph triglycerides
which is analogous to humans.130 In addition, insulin leads to activation of GLUT4 insulindependent glucose transporter and a feed-forward insulin release in both DM and
mammals; therefore, DM also a physiologically relevant model for diseases of insulinresistance despite initial concerns regarding different sugar metabolism than in
humans.107 Indeed, the mTOR pathway has shown to be overactive in a high-fat diet
induced obesity model using DM.130 In this model, inhibition of mTOR via rapamycin has
been shown to protect the heart and internal organs in DM from elevated hemolymph
triglycerides.130
The DM model of renal stone disease is a well validated model to study urolithiasis
due to its remarkable homology to humans (Figures 1.6, 1.7, and, 1.8).133,134 The basic
role of the urinary system is to filter, reabsorb and secrete solutes from the blood to and
from the urine. Once created, the urine is to be eliminated. In humans, the formation of
urine is accomplished by the nephron: which is comprised of the glomerulus, proximal
tubule, loop of Henle, distal tubule and collecting duct which does all of the filtering,
resorption and secretion (Figure 1.6A).34 The human glomerular vasculature is lined by
podocytes. Fluid then passes through the podocyte filter based on net interstitial pressure,
luminal pressure, interstitial osmolarity and luminal osmolarity (Figure 1.6B).
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Figure 1.6 Functional homology and structural differences between mammalian
nephrons and arthropod Malpighian tubules
(A) Mammalian nephron and (C) arthropod Malpighian tubule. (B) Podocytes and (D)
Nephrocytes importantly share fenestration properties that permit them to act as a semipermeable selective filtration barrier. (Weavers, Helen et al. “The Insect Nephrocyte Is a
Podocyte-like Cell with a Filtration Slit Diaphragm.” Nature 457.7227 (2009): 3220326.
PMC.) fp = foot process, sd = slit diaphragm, nd = nephrocyte diaphragm, bm = basement
membrane.
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Renal epithelial cells that make up the nephron then act to modify the
concentrations of substrates in the ultrafiltrate produced by the glomerulus.34 Urine is then
sent via the renal papilla into the minor calyces, major calyces, renal pelvis, ureter and
finally to the bladder to be eliminated when convenient per urethra. In contrast to humans,
DM circulatory system is avascular. Instead, DM have a complex fluid called “hemolymph”
that moves nutrients, wastes and hormones between structures in the fly.133 DM have an
analogous structures comparable to the glomerulus that filter hemolymph, called
nephrocytes (Figure1.6 C).133 The nephrocytes are located in the pericardium and have
a similar diaphragm, with small foot processes spaced 30nm apart with an underlying
basement membrane. Akin to the human podocytes, the nephrocyte foot processes form
a barrier to particle size and charge, resulting in filtration of the hemolymph (Figure 1.6
D).135 The filtered hemolymph then enters the Malpighian tubules, which is homologous
to the human tubular system of the nephron.135 There are four Malpighian tubules in a
DM, each comprised of three segments called the initial, transitional and main
segments.133,136 These segments are composed of either principal or stellate cells which
manage the ion concentration of the luminal aspect of Malpighian tubules. Finally, each
pair of Malpighian tubules join together to form a short “ureter” that connects the tubule
to the fly hindgut or cloaca (Figure 1.7).133
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Figure 1.7 Malpighian tubule (MT) segments.
(A) Principal cells dominate the initial and earl transitional segment of the MT whereas
the stellate cells are primarily found in the distal half of the transition and throughout the
main MT segments. (B) Principal and stellate cells with their respective ion and solute
transport mechanisms. Osmosis occurs transcellularly. (Denholm, Barry et al. “The
tiptop/teashirt genes regulate cell differentiation and renal physiology in Drosophila.”
Development (Cambridge, England) 140.5 (2013):1100-1110. PMC). MG = Midgut, HG =
Hindgut. V-ATPase = V-type adenosine-triphosphatase, cGMP = cyclic guanosine
monophosphate, cAMP = cyclic adenosine monophosphate, capa 1/2 = Capability
peptides 1 and 2, DH31/DH44 = Diuretic hormone 31 and 44, LK = Leucokinin, LKR =
Leucokinin receptor, BM = Basement membrane, SJ = Septate junction.
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DM have been used as a model for calcium oxalate nephrolithiasis since 2011.137
Although urolithiasis in this model is not spontaneous, it is relatively easy to form stones
via supplementation of lithogenic agents like ethylene glycol or sodium oxalate.133,138
Tubular concretions of calcium oxalate crystals are analogous to urinary stones and have
been confirmed by scanning electron microscopy and energy-dispersive x-ray
spectroscopy.138 Furthermore, due to the evolutionary conservation of ion channels and
cellular pathways between the Malpighian tubules and human nephrons, administration
of drugs known to impact certain types of stone formation like hydroxycitric acid have
worked in this model.139 Further advantages of this model include its high throughput
ability; consequently, DM can be an extremely economical in vivo model with lowmaintenance husbandry requiring relatively rudimentary equipment.114 In terms of the
study of stone burden, DM tubules are transparent, thus simple light microscopy allows
for the rapid and easy observation of calcium oxalate concretions without specialized
staining.
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Figure 1. 7 DM Malpighian Tubule anatomy.
A) Light micrograph of dissected (B) Artistic rendition of relevant DM anatomy for study
of nephrolithiasis. Each pair of Malpighian tubules are connected to the hindgut via a very
short (100 micrometer) “ureter”.133
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Hypothesis
Calcium oxalate crystals can activate mTOR and exacerbate the effect of ROS on
the formation and progression of calcium oxalate kidney stone disease.9 Therefore, we
hypothesize that calcium oxalate concretion formation in the Malpighian tubules of DM
treated with intermittent doses of rapamycin (an mTOR inhibitor) will be significantly less
than individuals not treated with rapamycin. We also hypothesize that treatment groups
fed a lithogenic diet while intermittently fasting every 24 hours on agar will have less
calcium oxalate concretions in their Malpighian tubules compared to a lithogenic
alternating with NF (ad libitum) diet early in the life of the fly. Additionally, mTOR inhibition
has also been associated with an increase in life expectancy in animal models.3 We
hypothesize that life expectancy of DM treated with rapamycin will be significantly longer
compared to control groups with and without lithogenic diets. Finally, we expect that
treatment groups fed a lithogenic diet while intermittently fasting every 24 hours on agar
early in the life of the fly will have longer life expectancy compared to ad libitum diets.
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Chapter 2
Materials and Methods
Ethics
DM are an invertebrate organism and as such experiments are exempt from
requiring animal ethics board approval. All insects were handled according to the
Canadian Council on Animal Care (CCAC) Guidelines140

DM Husbandry
CantonS (Stock #64349) wild type strain Drosophila flies were obtained from
Bloomington Stock Center, Indiana, USA (http://fly.bio.indiana.edu). All stocks were
maintained in plastic 50mL Erlenmeyer wide fly vials (Genesee Scientific Corporation,
CA). Stocks were stored separate from sample flies to avoid mite infestation. Twenty-five
to fifty DM individuals were mated for 18-24 hours on standard media with yeast paste
and grape agar. Flies that were no longer required were disposed of, in an Erlenmeyer
flask containing 70% ethanol. Eclosed (recently having emerged from the pupal state)
DM were allowed to mature 24 hours prior to first dose of anaesthesia, or treatment. Wide
fly vials (GEN32-121, Genesee Scientific, California, USA) were used for housing
samples during experimentation. At all times except for changing flies from vial to vial,
stocks were maintained in a DM incubator (DigiThermâ Drosophila Incubator, Tritech
Research Inc.) at a humidity of 40%, a temperature of 25°C, and were exposed to a 12hour light and 12-hour dark cycle.
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DM were transferred under gentle carbon dioxide (CO2) anaesthesia (Flystuff
Flowbuddy Flow Regulator with Ultimate Flypad, 590122BCU) for 5 seconds, for a total
of 10 seconds of hypoxia, from food medium to treatment agar in fly vials every 24 hours.
DM were observed for 10 minutes after anaesthesia transfer and any dead or escaped
individuals were censored from life-expectancy data. Food media and agar tubes were
changed every 5 days.

Production of DM food media
Individual batches of food media were produced in one-litre volumes. Ingredients
were weighed using a digital scale (Sartorius AG, Goettingen, Germany) and heated
using a hotplate in a non-sticking commercially available cooking pot. Freshly prepared
media was pipetted into the wide polypropylene vials using a disposable pipette. A grade
50 cheesecloth was placed to reduce the risk of contamination while cooling prior to
placement for storage. Vials were covered by cellulose acetate plugs (Flugs GEN49-101,
Diamed Inc., Ontario, Canada) and left to cool overnight to reduce condensation prior to
storage at 4°C. Unused vials of media were discarded if not used within 28 days.
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Standard food DM media and agar
Standard food as defined in this study was prepared according to a previously
utilized formula (Bloomington #1) which provided DM with adequate nutrients for
development in lab environment.141,142 (Table 2.1). One-thousand mL of distilled water
was brought to a rolling boil. Agar was added and stirred until clear. For agar tubes, this
mixture was allowed to cool and then poured into wide vials in 10mL aliquots. For all other
media, cornmeal was then stirred in until a thick formula formed. Yeast was then added
and stirred until dissolved. Corn syrup was then added prior to cooling. The mixture was
allowed to cool prior to adding propionic acid to media as a preservative. Finally, the
mixture was decanted in 10mL aliquots into wide vials as described previously.

Table 2.1 Ingredients used in the preparation of standard Drosophila lab media
(“Normal Food”).
For 0.1% sodium oxalate, 10mg oxalate was added to the mixture prior to pouring.
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Lithogenic DM media
Lithogenic food as defined in this study is 0.1% (weight/volume) sodium oxalate
(NaOx) dissolved in the standard DM food prior to cooling to room temperature. For each
replicate, normal media was separated by 50% volume. Five-hundred mL was poured
into a 1L beaker and 0.5mg of sodium oxalate was added to the mixture and stirred
thoroughly until fully dissolved. The ensuing lithogenic mixture was then decanted in
10mL aliquots into wide vials.
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Microcapillary rapamycin dosing
The CAFE method of drug delivery in DM has been previously described (Figure
2.1).143 Briefly, 5% agar is poured into the base of fly tubes. The cotton lids are pierced
by a 100 μL pipette and the same pipet is used to hold a fine capillary inside the vial
through the pipette tip. Using capillary action, approximately 5-10 μL aliquots of
rapamycin solution were loaded into the capillary. The fly tubes are then closed and the
capillary containing rapamycin and vehicle, or vehicle alone are placed in the pipette.
Flies in the experimental group were fed normal food media with dissolved 0.1%
(weight/volume) sodium oxalate (lithogenic media). The experimental group alternated
daily between a vial containing lithogenic media and a vial of non-nutritious 5% agar with
100 uM rapamycin dissolved in 10 μL of 100% ethanol and 5% sucrose (weight/volume)
accessible by a microcapillary. Our control groups were fed normal media alternating
every 24-hours on an agar tube. Each agar tube contained a capillary filled with 10 μL
ethanol and 5% sucrose (weight/volume) solution +/- 100 μM rapamycin (Figure 2.2). Our
positive control group alternated between standard and lithogenic media every 24h
without use of CAFE (Figure 2.2). All DM were placed on 5% agar (weight/volume) to
avoid desiccation.
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Figure 2.1 Diagram of the Capillary Feeder (CAFE) assay.
In this method of feeding, DM climb up the sides of the vial filled with agar and take up
substances within the capillary housed within the pipette tip. EtOH = 100% ethanol, w/v
= weight by volume.143
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Study design
Experimental and control diet groups were studied with both males and females
separated. Twenty flies per replicate were included in the positive control groups (Figure
2.2A). All experiments were performed over a duration of 10 days. Drosophila in in this
group were fed lithogenic food on day 1, anesthetized at the beginning of day 2 and
transferred to normal food for 24 hours. This was repeated for a total of 10 days.
Flies were fed lithogenic food on day 1, and then transferred to tubes containing
agar and a capillary with vehicle (ethanol + 5% sucrose) on a 5% agar base on day 2.
These media tubes were then alternated every 24 hours for 11 days post eclosure (Figure
2.2B). The negative control group was fed normal food on day 1, and then maintained on
a capillary containing ethanol with 5% sucrose on a 5% agar base for the remainder of
the experiment. The first experimental group alternated between normal food every 24
hours with 100µM rapamycin on 5% agar. The second experimental group alternated
between lithogenic food and 100µM rapamycin on 5% agar (Figure 2.2A). Five replicates
of each control and treatment group were performed to achieve an adequate number of
Malpighian tubules for analysis. No formal power calculation was calculated; however,
the number of flies required was determined based on previous study sample sizes in the
literature.132,137,138,144–147
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A

(Lithogenic)

B

1
1

Figure 2. 2Diagram of control and treatment groups.
(A) Daily alternating lithogenic (0.1% NaOx), or normal food with agar or normal food
identified by arrows. (B) Flowchart for experiments. The fly tubes were changed every 24
hours as marked by the X. On the 11th day post eclosure, each group was dissected for
Malpighian tubule analysis, whereas life expectancy vials were to continue until endpoint
or censoring was reached. X = Treatment day with rapamycin or vehicle on agar. NaOx
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= sodium oxalate, q24h = every 24 hours. Optimal dosing of rapamycin was not
determined in this study.
Malpighian tubule isolation
CO2 was used to euthanize DM at the completion of the experiment at 10 days.
DM were then transferred to a 1 mL Eppendorf tube containing 99% ethanol for 3 minutes,
and then to a Petri dish (Pyrex 3160100, Sigma-Aldrich Inc) lined with Sylgard (Dow
Corning Inc., MI, USA) that contained 10mL of phosphate-buffered saline (PBS) via fine
tipped forceps. DM dissections (Figure 2.4) were completed within 45 minutes of
immersion in PBS and placed in a solution of 37% formaldehyde diluted 9:1 with PBS for
one hour prior to being fixed on a slide for examination under the microscope.
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Figure 2.3 Malpighian tubule dissection via hindgut traction (HG). Malpighian tubules are
attached laterally (not shown) to the hindgut. (Drosophila image courtesy of Nicolas
Gompel, adapted for use under Creative Commons Attribution NC 3.0 Unported.)
Quantification of birefringent concretions in DM Malpighian tubules
Each group of DM were incubated for 10 days total. Flies received 5 days of the
lithogenic or nutrient containing food, and five days were spent with a daily dose of
rapamycin with 5% sucrose in ethanol or 5% sucrose in ethanol alone. All groups began
on non-lithogenic food for consistency. All Malpighian tubules were dissected on day 10,
where the last 24-hour period was on lithogenic to ensure maximal stone burden. The
degree of DM calcium oxalate concretions was defined as the total birefringent pixel area
per Malpighian tubule.
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Statistics
Life expectancy was analyzed via Kaplan-Meyer Curve, Cox Proportional Hazard
model and Log-Rank Test on R (Version 1.3.1093 © 2009-2020 RStudio, PBC).
Malphigian tubule concretion birefringence intensity was measured via ImageJ [ImageJ
Version 1.51(100)) pixel analysis (Rasband, W.S., ImageJ, U. S. National Institutes of
Health, Bethesda, Maryland, USA, https://imagej.nih.gov/ij/, 1997-2018]. When
appropriate, pixels were adjusted by dividing the total number of pixels by the number of
specimens represented in the image field. In order to approximate a normal distribution,
the number of pixels per MT in view for all groups were normalized by taking the squareroot of each measurement. Statistical analysis using SPSS (IBM SPSS Statistics v25) for
mean normalized pixel/MT for each group was analyzed with an analysis of variance
(ANOVA) with significance set at a p value < 0.05.
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Chapter 3
Results
DM Survival Analysis
In total 288 of 300 (96%) male and 299 of 300 (99.6%) female DM had end events
through 86 days of analysis (Table 3.1). Male DM on oxalate + rapamycin CAFE treatment
had lower survival compared to female DM on same treatment (23 days vs 49 days,
Table 3.1; HR 0.57, 95%CI: 0.40 – 0.82, p <0.001 Figure 3.2 and 3.3). Male DM on oxalate
+ rapamycin CAFE treatment had significantly shorter median survival compared to male
DM on normal food + rapamycin CAFE treatment (23 vs 35 days, Table 3.1; HR 0.61,
95% CI: 0.41 – 0.89, p-value = 0.01, Figure 3.1 and 3.3). Male DM on oxalate + rapamycin
CAFE treatment had significantly shorter median survival compared to male DM on
oxalate + normal food ad libitum treatment (23 vs 48 days, Table 3.1; HR 0.52, 95% CI:
0.36 – 0.75, p-value = <0.001, Figure 3.1 and 3.3). Male DM on oxalate + rapamycin
CAFE treatment had longer median survival compared to the oxalate + vehicle CAFE
treatment but did not reach threshold for significance (23 days vs 23 days, Table 1; HR
1.43, 95%CI: 1.00 – 2.05, p-value = 0.052, Figure 3.1 and 3.3).
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Male DM on normal food + rapamycin had significantly longer life expectancy than
male DM on oxalate + vehicle treatment (35 days vs 23 days, Table 1; HR: 2.34, 95%CI:
01.60 – 3.43, Figure 3.4). Male DM on normal food + rapamycin CAFE treatment had
significantly shorter median survival compared to female DM equivalent treatment (35
days vs 37 days, Table 1; HR 0.38, 95%CI: 0.26 – 0.95, p = 0.026, Figure 3.4). Male DM
treated with oxalate + vehicle had significantly shorter survival than female DM treated
with equivalent treatment (31 days vs 23 days, Table 1; HR 0.49, 95%CI 0.34 – 0.71, p <
0.001, Figure 3.3). No significant difference in median survival was seen between male
DM on oxalate + rapamycin CAFE treatment compared to male DM on normal food +
vehicle. Male DM on ad libitum lithogenic diet had no significant difference in survival
compared to male DM on normal food + rapamycin CAFE treatment (48 days vs 35 days,
HR 1.17, 95%CI: 0.80 – 1.7, p = 0.42, Figure 3.5). Male DM on ad libitum lithogenic diet
had longer median survival than male DM on normal food + vehicle CAFE treatment (HR
2.04, 95%CI 1.42 – 2.90, p < 0.001, Figure 3.5).
There was no significant difference in median survival between female DM on
oxalate + rapamycin CAFE treatment compared to other females (Figure 3.1 and 3.6).
Female DM on oxalate + vehicle treatment had significantly lower survival compared to
female DM on normal food + vehicle (31 days vs 33 days, Table 1; HR 0.66, 95%CI: 0.46
– 0.95, p = 0.024, Figure 3.6). Female DM on normal food + rapamycin CAFE treatment
had longer median survival compared to male DM on the same treatment (37 days vs 35
days, Table 3.1; HR 1.5, 95%CI: 1.04 – 2.20, p = 0.029, Figure 3.6). There was no
significant difference in median survival seen between male and female DM on ad libitum
lithogenic diet (Figure 3.2 and 3.7).
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Table 3.1 Kaplan-Meier survival data for Male and Female DM survival analysis.
N = sample size, Event = death, Ox Rap = 0.1% sodium oxalate + rapamycin, Ox V =
0.1% sodium oxalate + vehicle (no rapamycin). NF Rap = normal food + rapamycin. NF
V = normal food + vehicle. Ox NF = 0.1% sodium oxalate + normal food (Ad libitum
lithogenic diet).
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Figure 3.1 Kaplan-Meier survival curves for male (top) and female (bottom)
D. melanogaster given lithogenic or non-lithogenic diets, with or without rapamycin.
Vehicle denotes D. melanogaster cohorts that were fed non-nutritious solution without
rapamycin by CAFE. Reference cohort for comparison is 0.1% sodium oxalate +
rapamycin group for both males and females. Significance by Log-Rank test, levels: * =
p < 0.05, *** = p < 0.001.

61

Figure 3.2 Kaplan-Meier survival curves comparing ad libitum lithogenic diet treatment to
CAFE lithogenic treatment + rapamycin in female and male D. melanogaster.
Female 0.1% sodium oxalate + rapamycin group is reference curve for significance
testing by Log-Rank test. HR 1.76 (95%CI: 1.22 – 2.2.5). Significance level ** = p < 0.002.
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Figure 3.3 Forest plots of Hazard Ratios for male DM on lithogenic + rapamycin (top) or
vehicle (bottom) CAFE treatments.
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Figure 3.4 Forest plots of Hazard Ratios for male DM on normal food + rapamycin (top)
or vehicle (bottom) CAFE treatments.
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Figure 3.5 Forest plot of Cox Proportional Hazard Ratios for male DM on ad libitum
lithogenic treatment.

65

Figure 3. 6 Forest plots of Hazard Ratios for female DM on lithogenic + rapamycin (top)
or vehicle (bottom) CAFE treatments.
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Figure 3.7 Forest plots of Hazard Ratios for female DM on normal food with rapamycin
(top) or vehicle (bottom) CAFE treatments.
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Figure 3.8 Forest plots of Cox Proportional Hazard Ratios for female DM on ad libitum
lithogenic diet.
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Ex vivo imaging of Malpighian tubules and effect of rapamycin on concretion
birefringence.
Female DM who were available for full MT analysis ranged between 21 and 43
individual DM per treatment group (Table 3.2). The total of dissected MT for analysis
ranged from 67 to 104 per group in female DM and the median number Malpighian tubules
isolated intact is displayed in Table 3.5.

(m
edian)

Table 3.2 Descriptive statistics of female DM Malpighian tubules dissections for each diet.
Birefringence measured by square root transformed pixels per Malpighian tubule.
0.1%/NF = 0.1% sodium oxalate – normal food protocol. NF/+Rapa = normal food –
rapamycin protocol. NF/-Rapa = normal food without rapamycin. 0.1%/+Rapa = 0.1%
sodium oxalate – rapamycin protocol. 0.1%/- Rapa = 0.1% sodium oxalate without
rapamycin.
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Male DM in each group who were viable for full MT analysis ranged between 18
and 39 individual DM per group (Table 3.3), and had a total number of dissected MT of
45 to 122 per group for analysis. The median number of intact MT isolated per fly are
demonstrated in table 3.6.

Table 3.3 Descriptive statistics of male DM Malpighian tubules dissections for each diet.
0.1%/NF = 0.1% sodium oxalate – normal food protocol. NF/+Rapa = normal food –
rapamycin protocol. NF/-Rapa = normal food without rapamycin. 0.1%/+Rapa = 0.1%
sodium oxalate – rapamycin protocol. 0.1%/- Rapa = 0.1% sodium oxalate without
rapamycin.
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DM that did not get exposure to oxalate displayed very little birefringence
compared to groups treated with oxalate-based diets (Figure 3.9 D-E, I-J). Sex did not
affect Malpighian tubule birefringence when DM were fed equivalent diets (Figure 3.9).
There was no difference in MT birefringence in DM fed normal food without oxalate,
regardless of rapamycin treatment status.

Furthermore, there was no difference in

birefringence of DM on oxalate alternated with 24h of normal food (0.1%/NF) or vehicle
without rapamycin (0.1%/-Rapa).

Figure 3.9 Representative images of Malpighian tubules.
(A-E) Bright-field and (F-J) plane-polarized light microscopy at x 40 magnification for
dissected male and female DM Malphigian tubules at eleven days post-eclosure.
NF/0.1% = 0.1% sodium oxalate – normal food protocol. 0.1% = 0.1% sodium oxalate
protocol. NF = normal food protocol. Rapamycin treatment indicated by “+ Rap” (C, E, H,
J). White bar represents standardized distance of 500 μm.
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The oxalate/rapamycin dietary protocol resulted in significantly less mean MT
birefringence per Malpighian tubule compared to DM on both oxalate/normal food (16 vs
33, p < 0.01, Figure 3.10) and oxalate/vehicle protocols (16 vs 30, p < 0.01, Figure 3.10).
DM fed oxalate/rapamycin had significantly higher MT birefringence compared to DM fed
normal food with rapamycin (16 vs 3, p < 0.01, Figure 3.10) and normal food without
rapamycin (16 vs 4, p<0.01, Figure 3.10). Drosophila fed 0.1% oxalate/normal food had
significantly more MT birefringence compared to both normal food/vehicle (30 vs 3, p
<0.01, Figure 3.10) and normal food/rapamycin (30 vs 4, p<0.01, Figure 3.10) groups.
Male DM fed 0.1% oxalate/rapamycin had significantly lower MT birefringence
compared to 0.1% oxalate/normal food (19 vs 28, p < 0.01, Figure 3.10) and compared
to 0.1% oxalate/vehicle (16 vs 28, p <0.01, Figure 3.10). The oxalate/rapamycin protocol
had significantly greater mean normalized MT birefringence compared to DM fed normal
food protocols with rapamycin (16 vs 2, p<0.01, Figure 3.10) and without rapamycin (19
vs 4, p < 0.01, Figure 3.10).
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Figure 3.10 Box plot of DM normalized Malpighian tubule birefringence under
plane-polarized light microscopy.
Female = white and male = grey. 0.1%/NF = 0.1% sodium oxalate/normal food protocol.
NF/+Rapa = normal food/rapamycin protocol. NF/-Rapa = normal food without rapamycin.
0.1%/+Rapa = 0.1% sodium oxalate – rapamycin protocol. 0.1%/- Rapa = 0.1% sodium
oxalate without rapamycin. Significance indicated by *, p < 0.01.
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Chapter 4
Discussion
Survival analysis
Measuring life expectancy is simpler than measuring overall decline in function of
DM with advancing age and can be used as a crude surrogate for stress.148 The degree
of DM calcium deposition in the Malpighian tubule (MT) is associated with both oxalate
load and reduced life expectancy. Other studies have shown that MT concretions are
inversely correlated with life expectancy.138 As expected, calorie restricted lithogenic
diets are associated with significantly lower median survival compared to calorie restricted
non-lithogenic treatments in male DM. Intermittent dosing of rapamycin via CAFE extends
relative median survival of male DM fed a lithogenic diet compared to vehicle. Since
mTOR inhibition by rapamycin is known to induce autophagy86, we hypothesized that this
treatment would help reverse calcium oxalate crystal damage by improving the ability of
DM to clear ROS and damaged proteins.
We hypothesized that increased clearance of dysfunctional proteins and lower
ROS following rapamycin treatment would lead to an increase in life expectancy and
tolerance of calcium oxalate crystals. However, compared to available literature our
treatment did not improve life expectancy.138 However, our finding that rapamycin extends
the relative median life expectancy of wild type DM compared to vehicle is consistent with
other studies. For example, Wang et al. described a median survival advantage of a
mitochondrial dysfunction mutant of Drosophila treated with 100 µM of rapamycin daily
compared to vehicle (71 vs 62 days, a 14.5% increase).149
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Oxalate does also appear to be toxic to DM, resulting in lower relative life
expectancy. In these cases, rapamycin may improve survival independent of sodium
oxalate treatment. For context, the average life expectancy of DM ranges between 60 –
90 days and our DM given rapamycin on a lithogenic diet have a median survival of 33
days. Ali et al. reported very few DM fatalities before 20 days with median survival of
about 35 days for DM on an ad libitum lithogenic diet with 0.1% sodium oxalate.138,150 The
male DM given a lithogenic diet in our study have median survival of 33 and 27 days in
the rapamycin and vehicle groups respectively. In fact, the median ages of our DM in all
groups are shorter than in the literature.149–151 Our DM also appear to perish earlier in
their life cycle, with nearly 60% of deaths before 20 days of age.
We noted shorter overall life span and increased premature death in our DM
across all treatment groups compared to the available literature.138,150 Reduced life
expectancy may be related to the daily exposure to anaesthesia in order to change to
agar for the purpose of administering rapamycin via CAFE. Specifically, recurrent CO2
narcosis may have made our flies more susceptible to other causes of death such as
infection. Hypercarbia has been shown to decrease host resistance to bacterial infection
in Drosophila via upregulation of metabolic genes and reduced innate immune response
to infection.152 Unregulated host metabolism and poor resistance to infection may produce
ROS and impair the epithelial lining integrity of the Drosophila gut, in addition to altering
the homeostasis of Malpighian tubules.47,153
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Fan et al. have shown that rapamycin can rescue intestinal epithelial integrity and
improve life expectancy in a DM model of aging.153 Rapamycin and mTOR inhibition can
limit the harmful effect of reactive oxygen species by influencing the proliferation rate of
intestinal stem cells and immune cells,.153 Therefore, improvement in intestinal integrity
is a mechanism by which rapamycin may have improved relative median survival between
in DM fed a lithogenic diet. A competing hypothesis is that rapamycin acted on its
microenvironment to improve median survival. Rapamycin has known antifungal
properties that help ward off fungal organisms with pathologic potential in DM like C.
neoformans.100,154 Importantly, no macroscopic evidence of fungal infection was observed
in our study.
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Unexpectedly, male DM fed ad libitum calorie diet with alternating lithogenic days
had the longest median life expectancy. In other studies, lithogenic diet treatment has a
dose-dependent effect on reducing median life expectancy.138 Additionally, environments
of low nutrient availability should reduce mTOR activity, removing a barrier for autophagy
to occur.94 In particular, the rapamycin groups undergoing brief periods of dietary
restriction were expected to have longer life expectancy as seen by others who have
studied life span extension by by dietary restriction with and without rapamycin.82,155 In
the literature, rapamycin and dietary restriction are not equivalent, as they appear to act
in some cases synergistically to improve life expectancy.145,156 However, the CAFE
method of drug delivery in DM is known to have lower survival compared to equivalent
strains fed ad libitum.157 Additionally, our dietary restriction treatment may have allowed
for differential bacterial survival and create a hostile microenvironment. For example
alphaproteobacteria has been suggested as a bacterial taxon associated with longevity
in aging flies.158 It is known to be impacted by rapamycin treatment, which has
subsequently been linked to a mechanism for reduced mortality and health decline in
aged flies.158
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DM fed ad libitum alternating every other day with a lithogenic diet may have had
a the longest median survival in part due to the constant presence of propionic acid in its
environment. Propionic acid is a short-chain fatty acid (SCFA) that acts as a potent antifungal agent by inducing mercaptase-dependent apoptosis in eukaryotes.159,160
Furthermore, Propionibacterium and Lactobacilli are known to produce propionic acid as
a preservative by anaerobic fermentation of carbohydrates.161 Propionic acid derived from
food is also required for proper phospholipid membrane homeostasis in DM.162 Without
propionic acid supplementation, it is possible Lactobacilli and Propionibacterium are
outcompeted by other endogenous non-propionic acid producing microorganisms leading
to inefficient lipid metabolism and disordered epithelial defences. Other researchers have
suggested that changes in endogenous microflora leading to dysbiosis may have a
deleterious effect on DM lifespan via impaired immune or stem cell function, epithelial
barrier function or through direct infection by microorganisms.163–165
Intermittent treatment with rapamycin did not increase median survival for female
DM fed any diet. Furthermore, treatment-for-treatment, median life expectancy was
greater for female DM compared to male DM. It is a known phenomenon that male DM
are more sensitive to starvation and stress due to a greater tendency to move and
compete for limited resources compared to females, leading to quicker wasting of stored
lipids and proteins.166
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Additionally, it is know that male and female DM harbour different microbiota in
their environment.164 Therefore, they may have responded differently to our treatments
due to differences in microorganisms in their environment that was not controlled between
genders. This could be mitigated in the future by using gnotobiotic (a “known
microbiome”) or axenic (“germ free”) DM. Interestingly, the DM endogenous parasite
Wolbachia spp. is associated with increased larval male-specific death and an increase
in female median survival likely due to impaired oogenesis, reproductive function steroid
hormone metabolism and energy conservation.167,168 Furthermore, mTORC1 signalling
has been shown to suppress Wolbachia titres in oocytes, leading to reduced ecdysone
(steroid hormone) signalling that has been shown to significantly increase life expectancy
in DM.169 Since meiosis and reproduction is a non-life extending, energy-consuming
processes, inhibiting this process may allow female DM to tolerate stressful situations
better than male DM in our study.168
Another competing explanation is differential compensatory “binge eating” when
placed back in an ad libitum diet condition. This is in agreement with work by Farhadian
et al. that showed both male and female DM transiently increase their rate of food intake
following fasting.170 In fact, the female compensatory increase in rate of food intake lasted
for approximately 24-hours in their study; whereas, males returned to baseline feeding in
12-hours, a finding that has been reproduced by others.170,171 In our study, since females
lived longer it may be because of a higher overall intake of nutritious or antimicrobial
compounds following a period of fasting, helping them prevent confounding causes of
death from infection.
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Finally, it is possible that a fasting environment during treatment with either
rapamycin or vehicle of 24-hours duration is not adequate to achieve benefits of mTOR
inhibition. Furthermore, short intermittent fasting may be beneficial or harmful at different
points in the DM life cycle.155 Additionally, other authors have studied fasting durations
ranging from 24-hours to 7 days in duration.155,171,172 It is reasonable to assume therefore
that our fasted DM may not have received the full physiologic benefits of reduced mTOR
activity. Therefore, fasted DM would be at a survival disadvantage given less nutrients to
support on-going metabolic demands.
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Ex vivo crystal analysis
Drosophila melanogaster exposed to 0.1% sodium oxalate in their diet form highly
birefringent calcium oxalate monohydrate crystals in their Malpighian tubules.138 In
agreement with our hypothesis, rapamycin treatment resulted in fewer visible MT calcium
oxalate concretions compared to DM on other lithogenic diets. This result suggests that
intermittent rapamycin may reduce nephrolithiasis in our dietary Drosophila model of
calcium oxalate nephrolithiasis.
Our findings are primarily hypothesis generating for future study of the role of
mTOR in nephrolithiasis. First, calcium and oxalate are small substrates that can travel
across epithelial cell boundaries into the body through a paracellular mechanism.173,34
Calcium oxalate crystallization is dependent on the concentration of oxalate and calcium
in solution; therefore, gut homeostasis and effective oxalate uptake is an interesting target
for the prevention of nephrolithiasis. Worsening epithelial barrier function often leads to
increased paracellular transport of solutes.174 Indeed, impaired epithelial barrier function
in humans is seen following antibiotic treatment, fiber-poor diets high in processed foods,
patients with metabolic syndrome and obesity, and aging.175 Therefore, direct toxic insult
on epithelia and/or alterations of the gut microbiome may lead to a higher systemic
oxalate load and filtration into the Malpighian tubule lumen through increased oxalate
absorption from the gut.176 Fan et al. have demonstrated that rapamycin can rescue
epithelial stem cell function in older Drosophila with impaired gut barrier function and
homeostasis.153 Further study is required to confirm whether modulation of mTOR in DM
may impact oxalate uptake from a dietary source or whether it acts at the level of the
Malpighian tubule itself.
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An advantage of the DM model organism includes the possibility for future
organotypic studies via the UAS-GAL4 system.133 By employing a renal-specific (uro) and
UAS-GAL4 system targeting one of the interacting proteins in the mTOR pathway or
mTOR itself, one could elucidate whether mTOR activity is important at the level of
oxalate transport in the gut or via its action at the Malpighian tubule (Figure 4).

Figure 4 UAS-GAL 4 system with proposed Malpighian tubule tissue promoter uro genes
producing null mTOR mutant. This technique requires isolation of pure male DM with the
uro-GAL4 construct gene and pure female containing UAS-dTOR2L1. Upon activation of
uro by endogenous inducing transcription factors (TF), GAL4 is produced. The protein
product of Gal4 then interacts with the UAS region of the gene construct carrying the
mTOR mutant. This interaction leads to increased transcription of the desired gene
specifically at the site of the Malpighian tubule in all progeny.
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Second, rapamycin may upregulate autophagy leading to reduced calcium oxalate
MT concretion area. Though we did not quantify autophagy in our study, our results
support previous experiments by Unno et al. who showed improved efficiency of
autophagic flux in renal tubular cells exposed to calcium oxalate when treated with
rapamycin.9 Overall this led to decreased luminal calcium oxalate stone formation and
improved clearance of calcium oxalate crystals. There was a significant difference in
Malpighian tubule concretions in DM fed non – lithogenic ad libitum and all DM fed 0.1%
oxalate without rapamycin treatment. Therefore, rapamycin reduced the amount of
calcium oxalate concretions in Malpighian tubules, but it may not inhibit the crystallization
process completely. In other words, calcium oxalate nephrolithiasis still occurs; however,
the further aggregation and growth of calcium oxalate crystals may be hindered by
rapamycin treatment in our DM model.
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In some settings, autophagy may actually exacerbate stone formation. In contrast
to apoptosis which is a process of controlled cell death, autophagy is the process by which
cells recycle macromolecules.93 Duan et al. showed that chloroquine inhibition of
autophagy reduced tubular inflammation and calcium oxalate deposition.179 Indeed, their
study found that calcium oxalate crystals led to more immature apoptotic vesicle formation
at very high concentrations of oxalate (0.75 mM for 48h), a finding that was not seen in
the study by Unno et al. who used a nephrocalcinosis model of calcium oxalate formation
exacerbated by glycolate administration.9,179 The latter study may be more relevant for
the physiology of idiopathic calcium oxalate kidney stones in man. The study by Duan et
al used chloroquine in order to inhibit autophagy. Although chloroquine administration
does lead to inhibition of autophagy it also directly impairs cytoskeletal rearrangement
required for the management endoplasmic reticulum stress.180 The endoplasmic
reticulum is important for processing secreted proteins like Tamm-Horsfall protein, thus
potentially explaining why this mechanism of apoptosis inhibition may confound the study
of nephrolithiasis inhibtiors.63,180,181 However more research needs to be done on timing
of autophagic activation/inhibition in relation to serum oxalate load and mTOR inhibition.
Further support for rapamycin being positively associated with nephrolithiasis protection
includes work describing a reduction in tubulointerstitial inflammation and fibrosis in
obesity related renal conditions.71,182
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Importantly, there was some variability in the degree of stone burden within
individual DM of the rapamycin group fed a lithogenic diet. Furthermore, in both the
rapamycin and vehicle lithogenic diet groups, there is a 24-hour period where flies are
essentially calorically restricted to just a small amount of sucrose and either capillary
containing vehicle or rapamycin solution. There does not appear to be significantly lower
calcium oxalate MT concretions in calorically restricted compared to ad libitum caloric
intake on a lithogenic diet. This finding casts doubt on our hypothesis that fasting between
0.1% sodium oxalate loads reduces Malpighian tubule concretions through inhibition of
the mTOR pathway. However, it is possible that the duration of fasting in our study was
not adequate to inhibit mTOR similar to rapamycin treatment. As a result, we did not note
significant differences between our ad libitum diet conditions and those experiencing a
period of fasting on agar. It is known that the metabolic effects of dietary restriction, of
which fasting is a common strategy, is a complex endocrinologic process. Indeed, others
have found that the physiologic benefits of fasting may be enhanced by rapamycin and
are not purely mediated by mTOR activity.158
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Additionally, timing of dietary restriction in the life of DM may be important.
According to the pleiotropic hypothesis regarding the benefits surrounding autophagy and
mTOR inhibition, actions that are detrimental earlier in life may be beneficial later (and
vise versa).94 Interestingly, Catterson et al. found that if DM were fed only twice a week
until age 30 days, they had significantly longer life expectancy compared to DM who were
either always fasting on a 2:5 schedule until death or always ate ad libitum.155 DM that
fasted throughout life actually had the shortest life expectancy in the aforementioned
study.155 The fact that fasting is not a universally protective activity suggests a possible
epigenetic mechanism for its benefits.183 Given the correlation between non-metabolic
syndrome phenotype, aging, and relative protection from nephrolithiasis, further study on
this topic is needed to determine whether the benefits of different periods of fasting has
any true impact on nephrolithiasis pathogenesis.
Another hypothesis may be that rapamycin promotes the production of effective
natural stone-inhibitors. Theoretically, mTOR inhibition should improve autophagy and
rapidly clear dysfunctional or misfolded proteins in cells affected by inflammation.95 The
net result would be properly folded stone-inhibiting proteins secreted into urine. However,
this is a less likely hypothesis as primary cilia are absent in Drosophila renal tubules.177
Since primary cilia increases surface area for exchange of solutes, this suggests that
there may be lower bulk secretory and resorptive processes at the level of the Malpighian
tubule in DM compared to mammals.177 Indeed, in our literature search we could not
identify any articles suggesting a beneficial effect of rapamycin or mTOR inhibition on the
production of molecules like osteopontin, Tamm Horsfall protein or other endogenous
stone inhibitors involved in the dietary DM model of urolithiasis.
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Taken together, our findings suggest that calcium oxalate deposition in DM
Malpighian tubules does not require daily exposure to sodium oxalate and that the amount
concretion is reduced by rapamycin. Although fasting did not appear to influence overall
survival or Malpighian tubule calcium oxalate concretions, our data is inconclusive to
claim an effect on nephrolithiasis and further study is needed to clarify this. Treatment
with rapamycin appeared to help mitigate the adverse effect of sodium oxalate on both
median survival and Malpighian tubule concretions, and the mechanisms underlying this
are likely multifactorial. In addition, the gut microbiome and the effect of different genders
may have also impacted our results and should be accounted for in future studies.
Furthermore, rapamycin treatment may reduce mTOR activity exacerbated by calcium
oxalate crystals adherence to renal tubule-like epithelial cells. Reduced mTOR may
permit net clearance of damaged proteins that lead to inefficient clearance of lithogenic
substrates.
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Limitations and assumptions of study

Although we could have censored individuals that clearly died on transfer or by
trauma, it is not possible to know the cause of death of all DM subjects for certain and we
analyzed our life expectancy data in a non-informed manner to avoid bias. Furthermore,
we cannot definitively state whether or not confounding factors which affect life
expectancy influenced the weak correlation between stone formation and life expectancy
in our model. We do assume by equal treatment of all groups that confounding variables
should be minimized. We also cannot guarantee equal drug or nutrient uptake amongst
our Drosophila subjects. Since it is a closed environment with limited resources, some
individual DM may outcompete others for resources like sucrose in our CAFE system.
Therefore, some may be overdosed while others may be underdosed. This may explain
a rather large variation in stone burden seen in treatment groups containing 0.1% NaOx.
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Observation of large cohorts of age-matched Canton S Drosophila melanogaster
allows for population level information about the progression of aging and how treatments
impact this process.184 Arking et al found that longer Drosophila life span was related to
increased resistance to oxidative stress and by reducing the impact of oxidative damage
due to increased gene expression of antioxidant genes she could extend life
expectancy.185 In contrast to diets leading to metabolic syndrome, rapamycin and dietary
restriction have been shown to improve life expectancy in yeast, flies as well as mice in
part by limiting ROS.86,149 Though life span extension is associated with slower
senescence, shorter life spans are not necessarily associated with a “premature aging”
phenotype.186,187 In addition, body size and therefore mTOR activity may also vary in
CantonS DM themselves. Others have shown that variation in body size alone can explain
40% of variation in life expectancy.188 This variance may have produce a significant
amount of noise in the interpretation of life expectancy data in relation to unequal baseline
mTOR activity.188 We did not see extended life expectancy, therefore, the relative
improvement in survival seen in our study may be confounded by DM succumbing to
stressors unrelated to ROS, calcium oxalate concretions and/or mTOR inhibition.
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We chose pharmacologic inhibition of mTOR over a genetic model in Drosophila
for several reasons. Rapamycin is more readily available in reagent stock than available
mutants of mTOR in Drosophila that are not fatal before adulthood when the Malpighian
tubules are available for dissection. De novo screening for mTOR mutants would be
required in order to achieve this and this was not reasonably possible within the time
frame of this project. However, there are significant disadvantages when using
pharmacologic inhibition of mTOR with rapamycin. Due to the low water solubility, short
half-life in acidic environment such as DM food, uncertain compatibility in solution with
sodium oxalate and temperature instability of rapamycin in solution; rapamycin in our
model had to be delivered via CAFE capillary aliquots from a stock solution.189 An
inevitable complication of the CAFE method is unequal dosing between flies of the same
vial and survival stress. However, we would expect this to be randomly distributed in each
vial and not dependent on treatment group. Notably, the group with the greatest survival
was treated ad libitum without CAFE. Therefore, caloric restriction in the setting of a
lithogenic diet in future studies should be attempted without use of CAFE assay if
possible.
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In contrast to rodent models, Drosophila have an open circulatory system, and as
a result endothelial/vascular cell dysfunction is not easily modelled.133 Since Randall’s
plaques are thought to be of vascular origin, we cannot interrogate this area of
nephrolithiasis in DM.36,56,138,147 Given that mTOR activity is required for wound healing
and epithelial-to-mesenchymal cell transformation, this is an important short-coming of
the dietary DM model of nephrolithiasis and mTOR action. Furthermore the immune
system of Drosophila also differs greatly from humans.190 While others have shown the
activation of autophagy by mTOR inhibition may reduce Randall’s plaques, DM do not
form Randall’s plaques. Therefore, rapamycin may also act in other ways to prevent
nephrolithiasis.9
Though Drosophila is an excellent genetic model organism, “strong” direct mutants
of mTOR lead to arrest in embryological development and may not survive long into
adulthood.191 In addition, rapamycin also indirectly affects mTORC2 activity, which can
lead to a diabetic phenotype in face of increased sugar loads via relative β cell hypoplasia
of the pancreas depending on chronicity of use and expression of FKB-506 binding
proteins.192,193 Therefore, for control of when and for how long we could initiate mTOR
inhibition we decided to use a pharmacologic intervention in addition to our sodium
oxalate dietary strategy. Considering another alternative would be to repeat this study
protocol with a complete competitive antagonist of mTORC1 such as Torin1 or a water
soluble version of rapamycin – everolimus.194
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However, rapamycin is only a partial allosteric antagonist of mTORC1 at treatment
doses.101 The pharmacokinetic profile of rapamycin in DM is unknown, but the likely
distribution and therefore half-life is difficult to ascertain limiting efforts to optimize a
dosing schedule. For one, they have an erythrocyte analogue (hemocyte), it represents
less than 10% of its total hemolymph cells.195 In total, 95% of rapamycin is bound to
immunophilins in human erythrocytes. DM do have an analogue to cytochrome P450 3A4,
and therefore may have similar enzymatic processing of rapamycin into up to 16 different
metabolites.196 DM do not have an important role for estrogens, and females are generally
larger than males; therefore, from gender is expected to play a lesser role in the tissue
distribution and metabolism of rapamycin compared to humans.107,114,197
The DM model itself for the study of nephrolithiasis is not without its limitations.
Due to the lack of a vascular system and lymphoid structures, the biochemical and
inflammatory environment in DM are not analogous to humans. Furthermore, DM
normally feeds on high-sugar nutrients and has evolved adaptations necessary to prevent
hyperglycemia, such as storage of glucose as hemolymph trehalose.131 In addition,
utilizing a dietary model of DM stone disease requires a large sample size of flies in order
to reduce the variation in feeding habits of individual flies. Though DM are easy to house,
they are sensitive to dehydration and temperature changes198.
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Drosophila are also too small to ensure that each individual receives the same
amount of any dietary or drug intervention. The CApillary FEeding (CAFE) assay is a
common, well established method to circumvent the difficult problem of dosing
medications that may have low half-lives at specific temperatures or pH levels (Figure
2.1).143 Finally, DM hatch from a larval phase whereby they are constantly are feeding
and ambulatory, followed by a period of 3-4 days of fasting while awaiting to pupate into
their final fly form.198 Consequently, when studying mTOR which may be sensitive to
states of fasting, the results may not be applicable to humans as we do not typically have
these types of dietary patterns.
We are unable to claim that our rapamycin treatment reduced calcium oxalate
concretions due to direct mTOR inhibition. We also must assume that rapamycin did not
affect the feeding behaviour of DM to feed on the capillary solution. It has been shown
that DM do not consume all drugs administered by CAFE at the same rate.143 We also
assumed that the reason for improvements in life expectancy, as well as calcium oxalate
concretions, was due to direct DM mTOR inhibition rather than an effect on microbial
environment by rapamycin, a compound with known antibiotic and immunosuppressive
properties.100
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Ultimately, other studies are required to elucidate whether it is a drug phenomenon
of rapamycin on the environment, or, mTOR inhibition in DM that exacerbates
nephrolithiasis. For example, should a null-mutant mTOR Drosophila strain such as
dTOR2L1/dTORl(2)k17004 that is phenotypically smaller than CantonS show similar results
to our study it would strengthen the hypothesis that mTOR inhibition directly acts on DM
cells to influence nephrolithiasis rather than the environment. Additionally, if we repeated
our study in germ free DM it may refute the idea that rapamycin worked by modulating
the microbiological environment of our subjects leading to relative protection from
nephrolithiasis. In our fasting conditions, we may be missing the optimal duration or time
for fasting to prevent nephrolithiasis, limiting our ability to assess its impact. Furthermore,
without a measurement of apoptosis or protein synthesis, we cannot conclude which
mechanisms are important in stone prevention via rapamycin administration.
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Chapter 5
Conclusions and future directions
In conclusion, we are the first to demonstrate that intermittent rapamycin
administration by CAFE is effective at reducing calcium oxalate Malpighian tubule burden
in a dietary model of DM fed a 0.1% sodium oxalate diet every other day. In terms of
mTOR inhibition and its role in nephrolithiasis, our study supports the recent findings of
Unno et al. who suggested that rapamycin and mTOR inhibition reduce calcium oxalate
crystal growth in mice.9 Our study is novel as it suggests that intermittent dosing of
rapamycin may be adequate to inhibit calcium oxalate nephrolithiasis. Furthermore, this
work can be used as a pilot for further studies in Drosophila examining the mTOR pathway
in calcium nephrolithiasis. Though longer life expectancy did not occur with rapamycin
treatment, this may be confounded by limitations innate to using CAFE for drug delivery
including the lack of propionic acid supplementation, feeding rate controls, and the
possibility of microorganism involvement with a different gender predominance which may
have impacted our findings. In order to study whether fasting can resilience mitigate
calcium oxalate concretion formation, we can design relatively affordable optimization
studies to look at the optimal microenvironment, duration of fasting and/or oxalate loading
to reduce confounders.
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In order to confirm our statement that rapamycin affects calcium oxalate stone
formation, either at the level of the gut or Malpighian tubule epithelia, we would need to
measure the output of DM mTOR activity via p-S6K or p-eIFB4 to ensure DM had
physiologically relevant mTOR inhibition. However, systemic administration of rapamycin
would not allow us to elucidate if nephrolithiasis is protected by mTOR inhibition at the
level of the Malpighian tubular epithelia or gut in DM. To solve this, we would also need
to create tissue-specific mutants in order to achieve knowledge of the tissue most
important for prevention of nephrolithiasis in our model.
To accomplish the goal of identifying where mTOR is most needed in the
prevention of nephrolithiasis, DM can be used generate tissue-specific mutants via the
UAS-GAL4 system.177 In this genetic method, a tissue-specific promotor region of DNA is
combined with the GAL4 gene, a transcription factor.199 Once GAL4 is produced in the
tissue of interest, it can bind the UAS promoter and drive the expression of any gene of
interest. For example, we could generate UAS-GAL4 flies with a uro promoter region, and
drive the expression of a weak functionally null-mutant of mTOR like dTOR2L1 only in the
Malpighian tubule (Figure 4). This is possible because of the specificity of uro for
Malpighian tubule structures. If this model were to show reduced calcium oxalate burden,
it would strengthen the hypothesis that mTOR activity is important at the level of the
Malpighian tubule rather than elsewhere. We could also examine the effect of
pharmacologic inhibition of mTOR on a knockout model of autophagy to determine the
necessity of autophagy for protection by mTOR inhibition.
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Finally, to date mTOR inhibition has only been interrogated for calcium-based
urolithiasis. Since metabolic syndrome is associated with uric acid stones as well as
calcium oxalate stones, it would be interesting to determine the impact of rapamycin
treatment or genetic mTOR inhibition in non-calcium oxalate stones that are also
associated with aging and metabolic excess. This could be accomplished with a DM uric
acid model of urolithiasis, which our group has previously developed.134
Overall, we conclude that inhibition of mTOR activity shows promise in reduction
of calcium oxalate stone prevention in a dietary Drosophila melanogaster model of
nephrolithiasis. In particular, we are the first to show that calcium oxalate concretions can
be created with intermittent sodium oxalate treatment. Furthermore, we show that these
concretions can be significantly reduced in Drosophila melanogaster by intermittent
rapamycin treatment delivered via a capillary feeding system. This is important evidence
as it supports the creation of genetic DM models to further investigate which metabolically
active pathways downstream from the mTOR pathway are most strongly associated with
prevention of calcium oxalate concretions. Once the downstream mTOR pathways with
the most potential impact on calcium oxalate crystal formation are identified, these may
then be targeted for further study in mammalian models. Ultimately, this pilot project will
inform future work on incorporating mTOR pathway in our dietary DM model of
nephrolithiasis.
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